The patient, their doctor, the regulator and the profit maker: Conflicts and possible solutions

Clinical Microbiology and Infection

Volumn 7, Issue SUPPL. 6, 2001, Pages 27-30

  Monnet, D L ^a   Sorensen, T L ^a  

^a STATENS SERUM INSTITUT   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT;

ARTICLE; DENMARK; DRUG CONTROL; DRUG INDUSTRY; DRUG UTILIZATION; ECONOMICS; HUMAN; LEGAL ASPECT; PATIENT EDUCATION; PRIMARY HEALTH CARE; STANDARD;

ANTI-BACTERIAL AGENTS; DENMARK; DRUG AND NARCOTIC CONTROL; DRUG INDUSTRY; DRUG UTILIZATION; HUMANS; PATIENT EDUCATION; PRIMARY HEALTH CARE;

EID: 0035753571     PISSN: 1198743X     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1469-0691.2001.00083.x     Document Type: Article

References (24)

1. Bauraind I, Vanden Bremt I, Bogaert M et al. Evaluation of the impact of a public campaign for a more rational use of antibiotics in Belgium (Abstract L 3-9). In: 41st ICAAC Final Programme, Abstracts and Exhibits Addendum. Chicago, Illinois. Washington, DC: American Society for Microbiology, 2001.
2. Holmes B. Life at the sharp end of prescribing: influences, responsibilities and blame. Clin Microbiol Infect 2001; 7 (Suppl. 6): 9-11.
3. European Federation of Pharmaceutical Industries Associations. European code of practice for the promotion of medicines. Brussels: European Federation of Pharmaceutical Industries Associations, 1993. Available from: URL: htrp:// www.efpia.org/6_publ/codecon/Promomedicin_.pdf
4. Becel B, Bardelay D, 't Hoen E. Prescrire Editorial Board. A French physician's network monitoring medical representatives [Poster 4P-12]. First International Conference on Improving Use of Medicines, Chiang Mai, Thailand. 1997. Available from: URL: http://www.who.int/dapicium/posters/4P12_text.html
5. LIBRA Available from: URL: http://www.librainitiative.com/index_-en.html (accessed 15 May 2001).
6. Edlund C, Nord CE. Effect of quinolones on intestinal ecology. Drugs 1999; 58 (Suppl 2): 65-70.
7. Hoiby N, Jarlov JO, Kemp M et al. Excretion of ciprofloxacin in sweat and multi-resistant Staphyhcoccus epidermidis. Lancet 1997; 349: 167-9.
8. Friis H, Bro F, Mabeck CE, Vejlsgaard R. Changes in prescription of antibiotics in general practice in relation to different strategies for drug information. Dan Med Bull 1991; 38: 380-2.
9. Justesen T, Korsager B, Scheibel J. Vejledning i brug af antibiotika. In: J Aldershvile, MS Hansen, JP Kampmann, B Vej-Hansen, eds. Lægeforeningens Medicinfortegnelse 1999. 22nd edn. Copenhagen: Lægeforeningens Forlag, 1999: 827-51.
10. van der Meer JWM, Gyssens IC. Quality of antimicrobial drug prescription in hospital. Clin Microbiol Infect 2001; 7 (Suppl. 6): 12-15.
11. Durrant C. The responsibility of the pharmaceutical industry. Clin Microbiol Infect 2001; 7 (Suppl. 6): 2-4.
12. Brichacek A. Special report. Top 50 pharmaceutical companies of 2000. Pharmaceutical Executive 2001 (April): 62-6, 68, 72, 74, 76, 78, 80, 82. Available from: URL: http://www.pharmaportal.com/articles/pe/pe0401_062-82.pdf
13. The Fortune 500. Top performing industries. Available from: URL: http:// www.fortune.com/indexw.jhtml?channel=list.jhtml&list_frag=list_f5_ ind_index.jhtml
14. The pharmaceutical industry: 10 trends to watch (Press release). Newtown, PA: Quintiles Transnational, June 19 2001. Available from: URL: http:// www.quintiles.com/products_and_services/informatics/scott_levin/ press_releases/press_release/1,2226,233,00.html
15. IMS Health reports. US pharmaceutical promotional spending topped $8 billion in first-half 2000. London: IMS Health, October 19, 2000. Available from: URL: http://www.imhealth.com/public/structure/dispcontent/ 1,2779,1203-1203-82229,00.html
16. IMS Health reports. Worldwide pharmaceutical market-12 months to December 2000. London: IMS Health, 2001 Available from: URL: http://www.af-pharmacists.org/documents/WorldRxSalesALL00.pdf
17. The Europe 500. New York: Dow Jones & Company Inc, 2001. Available from: URL: http://interactive.wsj.com/public/resources/documents/europe500list-06112001.htm
18. Angell M. The pharmaceutical industry-to whom is it accountable? N Engl J Med 2000; 342: 1902-4.
19. Tsiodras S, Gold HS, Sakoulas G et al Linezolid resistance in a clinical isolate of Staphylococcus aureus. Lancet 2001; 358: 207-8.
20. DANMAP 2000. Consumption of antimicrobial agents and occurrence of antimicrobial resistance in bacteria from food animals, foods and humans in Denmark. Copenhagen: Danish Veterinary Laboratory, 2001. Available from: URL: http:// www.svs.dk/dk/Organisation/z/forsider/Danmap %20forsider.htm
21. Monnet DL, Sorensen TL, Johansen HL, López-Lozano JM. Impact of a reimbursement policy on antimicrobial prescriptions in the primary health care sector, Denmark, 1994-98: a time-series analysis (abstract O180). In: Abstracts of the 39th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA. Washington DC: American Society for Microbiology, 1999; 733.
22. Goossens H, Sion JP, Peetermans WE, Bossens M. Implementing perioperative antibiotic use in Belgian hospitals through evidence-based limited reimbursement by the health insurance. (Abstract 111). In: Abstracts of the 40th Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, Canada. Washington DC: American Society for Microbiology, 2000; 503.
23. Gould IM. Minimum antibiotic stewardship measures. Clin Microbiol Infect 2001; 7 (Suppl. 6): 22-26.
24. European Federation of Pharmaceutical Industries Associations. Position paper: containment of antibacterial resistance. Brussels: European Federation of Pharmaceutical Industries Associations, 2001. Available from: URL: http:// www.efpia.org/4_pos/sci_regu/antimicrobial.pdf